Справка
x
Поиск
Закладки
Озвучить книгу
Изменить режим чтения
Изменить размер шрифта
Оглавление
Для озвучивания и цитирования книги перейдите в режим постраничного просмотра.
Атопический дерматит
Список литературы
Поставить закладку
Palmer C.N., IrvineA.D., Terron-KwiatkowskiA. etal. Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. Nat. Genet. 2006; 38: 441–446.
McGirtL.Y., BeckL.A. Innate immune defects in atopic dermatitis. J Allergy Clin Immunol. 2006;118:202–208
Bao L., Zhang H., Chan L.S. The involvement of the JAK-STAT signaling pathway in chronic inflammatory skin disease atopic dermatitis. JAKSTAT. 2013; 2(3) e24137
Gandhi N.A., Pirozzi G., Graham N.M. Commonality of the IL-4/IL-13 pathway in atopic diseases. Expert Rev Clin Immunol. 2017;13(5):425–437.
Werfel T., Allam J.P., Biedermann T. et al. Cellular and molecular immunologic mechanisms in patients with atopic dermatitis. J Allergy Clin Immunol 2016; 138: 336–349.
Wollenberg A., Barbarot S., Bieber T. et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I.J Eur Acad Dermatol Venereol. 2018;32(5): 657–682.
Кубанов А.А., Богданова Е.В.Организация и результаты оказания медицинской помощи по профилю дерматовенерология в Российской Федерации. Итоги 2018 года. Вестникдерматологииивенерологии. 2019; 95 (4): 8–23.
Schneider L., Hanifin J., Boguniewicz M. et al. Study of the atopic march: development of atopic comorbidities. Pediatr Dermatol. 2016;33(4):388–398.
Bieber T.Atopic dermatitis 2.0: from the clinical phenotype to the molecular taxonomy and stratified medicine. Allergy. 2012; 67 (12); 1475–1482.
van der Hulst A.E., Klip H., Brand P.L. Risk of developing asthma in young children with atopic eczema: a systematic review. J Allergy Clin Immunol 2007; 120: 565–569.
Eckert L., Gupta S., Amand C. et al. The burden of atopic dermatitis in US adults: Health care resource utilization data from the 2013 National Health and Wellness Survey. J AmAcadDermatol 2018; 78: 54–61.
Illi S., von Mutius E., Lau S. et al. The pattern of atopic sensitization is associated with the development of asthma in childhood. J Allergy Clin Immunol. 2001;108: 709–714.
Aw M., Penn J., Gauvreau G.M. et al. Atopic March: Collegium InternationaleAllergologicum Update 2020.Int Arch Allergy Immunol. 2020;181(1):1–10.
Spergel J.M. Epidemiology of atopic dermatitis and atopic march in children. Immunol Allergy Clin N Am. 2010; 30: 269–280.
Hill D.A., Spergel J.M. The atopic march: Critical evidence and clinical relevance. Ann Allergy Asthma Immunol. 2018;120(2):131–137.
Williams H., Flohr C. How epidemiology has challenged 3 prevailing concepts about atopic dermatitis. J Allergy Clin Immunol. 2006; 118:209–213.
Illi S., von Mutius E., Lau S. et al. The natural course of atopic dermatitis from birth to age 7 years and the association with asthma. JAllergyClinImmunol. 2004; 113:925–931.
Атопический дерматит: рекомендации для практических врачей. Российский согласительный национальный документ по атопическому дерматиту. Под ред. P.M. Хаитова, А.А. Кубановой. М.: Фармакус Принт, 2002. 192 с.
Hanifin JM, Rajka G. Diagnostic features of atopic dermatitis. Acta DermVenereol. 1980;92(Suppl):44–47.
Eichenfield L.F., Tom W.L., Chamlin S.L. et al. Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis. J Am Acad Dermatol. 2014;70(2):338–351.
Ryan C., Amor K.T., Menter A. The use of cyclosporine in dermatology: part II.J Am Acad Dermatol. 2010;63(6):949–972.
Arbes S.J. Jr. Gergen P.J., Elliott L., Zeldin D.C. Prevalences of positive skin test responses to 10 common allergens in the US population: results from the third National Health and Nutrition Examination Survey. J Allergy Clin Immunol. 2005; 116:377–383.
Клиническая дерматовенерология: в 2 т. / под ред. Ю.К. Скрипкина, Ю.С. Бутова. – М.: ГЭОТАР-Медиа, 2009. – т.II. – 928 с.
Futamura M., Leshem Y.A., Thomas K.S. et al. A systematic review of Investigator Global Assessment (IGA) in atopic dermatitis (AD) trials: Many options, no standards. J Am Acad Dermatol. 2016;74(2):288–294.
Oranje A.P., Stalder J.F., Taieb A.et al. Scoring of atopic dermatitis by SCORAD using a training atlas by investigators from different disciplines. ETAC Study Group. Early Treatment of the Atopic Child. Pediatr Allergy Immunol. 1997; 8:28–34.
Schram M.E., Spuls P.I., Leeflang M.M. et al. EASI, (objective) SCORAD and POEM for atopic eczema: responsiveness and minimal clinically important difference. Allergy. 2012; 67:99–106.
Giam Y.C., Hebert A.A., Dizon M.V. A review on the role of moisturizers for atopic dermatitis. Asia Pac Allergy. 2016;6 (2):120–128.
Breternitz M., Kowatzki D., Langenauer M. et al. Placebo-controlled, double-blind, randomized, prospective study of a glycerol-based emollient on eczematous skin in atopic dermatitis: biophysical and clinical evaluation. Skin Pharmacol Physiol. 2008; 21: 39–45.
Verallo-Rowell V.M., Dillague K.M., Syah-Tjundawan B.S. Novel antibacterial and emollient effects of coconut and virgin olive oils in adult atopic dermatitis. Dermatitis. 2008;19 (6): 308–315.
Simpson E., Dutronc Y. A new body moisturizer increases skin hydration and improves atopic dermatitis symptoms among children and adults. J Drugs Dermatol. 2011;10: 744– 749.
Lindh J.D., Bradley M. Clinical effectiveness of moisturizers in atopic dermatitis and related disorders: a systematic review. Am J Clin Dermatol. 2015; 16: 341–359.
Miller D.W., Koch S.B., Yentzer B.A. et al. An over-the-counter moisturizer is as clinically effective as, and more cost-effective than, prescription barrier creams in the treatment of children with mild-to-moderate atopic dermatitis: a randomized, controlled trial. J DrugsDermatol. 2011; 10: 531–537.
Grimalt R., Mengeaud V., Cambazard F. The steroid-sparing effect of an emollient therapy in infants with atopic dermatitis: a randomized controlled study. Dermatology. 2007; 214 (1): 61–67.
Msika P., De Belilovsky C., Piccardi N. et al. New emollient with topical corticosteroid- sparing effect in treatment of childhood atopic dermatitis: SCORAD and quality of life improvement. Pediatr Dermatol. 2008; 25 (6): 606–612.
Lucky A.W., Leach A.D., Laskarzewski P., Wenck H. Use of an emollient as a steroid- sparing agent in the treatment of mild to moderate atopic dermatitis in children. Pediatr Dermatol. 1997; 14 (4): 321–324.
Eberlein B., Eicke C., Reinhardt H.W., Ring J. Adjuvant treatment of atopic eczema: assessment of an emollient containing N-palmitoylethanolamine (ATOPA study). J Eur Acad Dermatol Venereol. 2008; 22 (1): 73–82.
Sugarman J.L., Parish L.C. Efficacy of a lipid-based barrier repair formulation in moderate- to-severe pediatric atopic dermatitis. J Drugs Dermatol. 2009; 8 (12): 1106–1111.
Leung T.N., Chow C.M., Chow M.P. et al. Clinical guidelines on management of atopic dermatitis in children. Hong Kong J Paediatr (new series). 2013; 18: 96–104.
Darsow U., Wollenberg A., Simon D. et al. ETFAD/EADV Eczema Task Force 2009 position paper on diagnosis and treatment of atopic dermatitis. J Eur Acad Dermatol Venereol. 2010; 24 (3): 317–328.
Chiang C., Eichenfield L.F. Quantitative assessment of combination bathing and moisturizing regimens on skin hydration in atopic dermatitis. PediatrDermatol. 2009; 26 (3): 273–278.
Guidance on Prescribing. In: British National Formulary No.60. London: British Medical Association and Royal Pharmaceutical Society of Great Britain; 2010.
Dabade T.S., Davis D.M., Wetter D.A. et al. Wet dressing therapy in conjunction with topical corticosteroids is effective for rapid control of severe pediatric atopic dermatitis: experience with 218 patients over 30 years at Mayo Clinic. J Am Acad Dermatol. 2012; 67 (1):100–106.
Devillers A.C., Oranje A.P. Efficacy and safety of ‘wet-wrap’ dressings as an intervention treatment in children with severe and/or refractory atopic dermatitis: a critical review of the literature. Br J Dermatol. 2006; 154 (4):579–585.
Devillers A.C., de Waard-van der Spek F.B., Mulder P.G., Oranje A.P. Treatment of refractory atopic dermatitis using ‘wet-wrap’ dressings and diluted corticosteroids: results of standardized treatment in both children and adults. Dermatology. 2002; 204:50–55.
Goodyear H.M., Spowart K., Harper J.I. ‘Wet-wrap’ dressings for the treatment of atopic eczema in children. Br J Dermatol. 1991; 125 (6):604.
Brenninkmeijer E.E., Spuls P.I., Lindeboom R. et al. Excimer laser vs. clobetasol propionate 0·05% ointment in prurigo form of atopic dermatitis: a randomized controlled trial, a pilot. Br J Dermatol. 2010; 163 (4): 823–831.
Pels R., Sterry W., Lademann J. Clobetasol propionate – where, when, why? Drugs Today (Barc). 2008; 44 (7): 547–557.
Breneman D., Fleischer A.B. Jr, Kaplan D. et al. Clobetasol propionate 0.05% lotion in the treatment of moderate to severe atopic dermatitis: a randomized evaluation versus clobetasol propionate emollient cream. J Drugs Dermatol. 2005; 4 (3): 330–336.
Feldman S.R. Relative efficacy and interchangeability of various clobetasol propionate vehicles in the management of steroid-responsive dermatoses. CurrTher Res ClinExp. 2005; 66 (3): 154–171.
Datz B., Yawalkar S. A double-blind, multicenter trial of 0.05% halobetasol propionate ointment and 0.05% clobetasol 17-propionate ointment in the treatment of patients with chronic, localized atopic dermatitis or lichen simplex chronicus. J AmAcadDermatol. 1991; 25 (6 Pt 2): 1157–1160.
Viglioglia P., Jones M.L., Peets E.A. Once-daily 0.1% mometasone furoate cream versus twice-daily 0.1% betamethasone valerate cream in the treatment of a variety of dermatoses. J Int Med Res. 1990; 18 (6): 460–467.
Vanderploeg D.E. Betamethasone dipropionate ointment in the treatment of psoriasis and atopic dermatitis: a double-blind study. South Med J. 1976; 69 (7): 862–863.
Queille C., Pommarede R., Saurat J.H. Efficacy versus systemic effects of six topical steroids in the treatment of atopic dermatitis of childhood. Pediatr Dermatol. 1984; 1 (3): 246–253.
Cabrera M.E. Treatment of severe or resistant corticosteroid-responsive dermatoses with Diprolene cream. J Int Med Res. 1984; 12 (3) :163–169.
Lodolo J.C.Diprolene cream in the treatment of severe or resistant corticosteroid-responsive dermatoses. J Int Med Res. 1984; 12 (2): 114–120.
Peterkin G.A., Morley W.N., Chalmers D. Triamcinolone and fluocinolone acetonide ointments in atopic eczema. BrMed J. 1962; 1 (5289): 1392.
Hanifin J.M. Atopic dermatitis. Special clinical complications. Postgrad Med. 1983;74(3):188–193, 196–199.
Cadmus S.D., Sebastian K.R., Warren D. et al. Efficacy and patient opinion of wet‐ wrap dressings using 0.1% triamcinolone acetonide ointment vs cream in the treatment of pediatric atopic dermatitis: A randomized split‐ body control study. PediatrDermatol. 2019; 36 (4): 437–441.
Wolkerstorfer A., Strobos M.A., Glazenburg E.J. et al. Fluticasone propionate 0.05% cream once daily versus clobetasone butyrate 0.05% cream twice daily in children with atopic dermatitis. J Am Acad Dermatol. 1998; 39 (2 Pt 1): 226–231.
Bleehen S.S., Chu A.C., Hamann I. et al. Fluticasone propionate 0.05% cream in the treatment of atopic eczema: a multicentre study comparing once-daily treatment and once- daily vehicle cream application versus twice-daily treatment. Br J Dermatol. 1995; 133 (4): 592–597.
Белоусова Т.А., Горячкина М.В. Опыт применения флутиказона пропионата (Кутивейт) в терапии псориаза, экземы и атопического дерматита. Эффективная фармакотерапия. 2010; 9: 24–29.
Prakash A., Benfield P.Topical mometasone. A review of its pharmacological properties and therapeutic use in the treatment of dermatological disorders.Drugs. 1998;55(1):145–163.
Vernon H.J., Lane A.T., Weston W. Comparison of mometasone furoate 0.1% cream and hydrocortisone 1.0% cream in the treatment of childhood atopic dermatitis. J Am Acad Dermatol. 1991; 24 (4): 603–607.
Lebwohl M. A comparison of once-daily application of mometasone furoate 0.1% cream compared with twice-daily hydrocortisone valerate 0.2% cream in pediatric atopic dermatitis patients who failed to respond to hydrocortisone: mometasone furoate study group. Int J Dermatol. 1999; 38 (8): 604–606.
Томилова А.Ю., Торшхоева Р.М., Геворкян А.К., Вознесенская Н.И. Эффективность и безопасность применения мометазонафуроата при атопическом дерматите у детей. Педиатрическая фармакология 2009; 6 (4): 123–127.
Шаипов Т.С., Мазитова Л.П. Применение мометазонафуроата при лечении атопического дерматита у детей. Педиатрическая фармакология. 2007; 4 (5): 41–44.
Ненашева Н.М. Особенности атопического дерматита у взрослых пациентов Эффективная фармакотерапия. Дерматовенерология и дерматокосметология. 2012; (3): 6–15.
Lane A.T. Efficacy and safety of topical steroids in paediatric atopic dermatitis. J Eur Acad Dermatol Venereol. 1997; 8: S24–S27.
Faergemann J., Christensen O., Sjövall P. et al. An open study of efficacy and safety of long‐ term treatment with mometasone furoate fatty cream in the treatment of adult patients with atopic dermatitis. J Eur Acad Dermatol Venereol. 2000; 14 (5): 393–396.
Haneke E. The treatment of atopic dermatitis with methylprednisolone aceponate (MPA), a new topical corticosteroid. J DermatolTreatm. 1992; 3 (Suppl.2): 13–15.
Luger T.A. Balancing efficacy and safety in the management of atopic dermatitis: the role of methylprednisolone aceponate. J EurAcadDermatolVenereol. 2011; 25 (3): 251–258.
Bieber T., Vick K., Fölster-Holst R. et al. Efficacy and safety of methylprednisolone aceponate ointment 0.1% compared to tacrolimus 0.03% in children and adolescents with an acute flare of severe atopic dermatitis. Allergy. 2007; 62 (2): 184–189.
Кондратьева Ю.С., Кархова В.В. Опыт применения 0,1% метилпреднизолонаацепоната в комплексной терапии стероидчувствительных дерматозов. Вестник дерматологии и венерологии 2016; 1: 93–98.
Чикин В.В. Метилпреднизолонаацепонат и декспантенол в топической терапии больных атопическим дерматитом. Вестникдерматологииивенерологии 2014; 5: 112– 116.
Lassus A. Alclometasone dipropionate cream 0.05% versus clobetasone butyrate cream 0.05%. A controlled clinical comparison in the treatment of atopic dermatitis in children. Int J Dermatol. 1984; 23 (8): 565–566.
Panja S.K., Gangopadhaya A.K., Sharma S.D. A randomised, double-blind comparison of alclometasone dipropionate 0.05% cream in atopic dermatitis and other dermatoses. Indian J Dermatol. 1988; 33 (1): 1–4.
Макарова И.В., Гайдук И.М., Жиглинская О.В и др. Применение 0,05% крема алклометазонадипропионата в терапии атопического дерматита у детей раннего возраста. Вопросы современной педиатрии. 2004; 3 (4): 84–87.
Короткий Н.Г., Тихомиров А.А., Гамаюнов Б.Н. Оценка клинической эффективности современного стероида алклометазонадипропионата (Афлодерма) в наружной терапии атопического дерматита у детей. Клиническая дерматология и венерология. 2007; 6: 24–31.
Торопова Н.П., Черкасова Л.А., Платонова И.Н. и др. Опыт применения препарата «Афлодерм» (алклометазонадипропионат) в детской дерматологической практике. Российский журнал кожных и венерических болезней. 2003; 3: 39–40.
Veien N.K., Hattel T., Justesen O. et al. Hydrocortisone 17-butyrate (Locoid) 0.1% cream versus hydrocortisone (Uniderm) 1% cream in the treatment of children suffering from atopic dermatitis. J Int Med Res. 1984; 12 (5):310–313.
Rajka G., Verjans H.L. Hydrocortisone 17-butyrate (Locoid) 0.1% fatty cream versus desonide (Apolar) 0.1% ointment in the treatment of patients suffering from atopic dermatitis. J Int Med Res. 1986; 14 (2): 85–90.
Abramovits A, Oquendo M. Hydrocortisone butyrate 0.1% lipocream in pediatric patients with atopic dermatitis. SKINmed. 2010; 8: 72–79.
Koopmans B., Lasthein Andersen B., Mork N.J. et al. Multicentre randomized double-blind study of locoidlipocream fatty cream twice daily versus locoidlipocream once daily and locobase once daily. J Dermatol Treat. 1995;6 (2): 103–106.
Saki N, Jowkar F, Alyaseen S. et al. Comparison of sertaconazole 2% cream versus hydrocortisone 1% ointment in the treatment of atopic dermatitis. J Dermatolog Treat. 2013;24 (6): 447–449.
Reitamo S., Rustin M., Ruzicka T. et al. Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone butyrate ointment in adult patients with atopic dermatitis. J Allergy Clin Immunol. 2002; 109 (3): 547–555.
Matheson R., Kempers S., Breneman D. et al. Hydrocortisone butyrate 0.1% lotion in the treatment of atopic dermatitis in pediatric subjects. J Drugs Dermatol. 2008; 7 (3): 266–271.
Sears H.W., Bailer J.W., Yeadon A. Efficacy and safety of hydrocortisone buteprate 0.1% cream in patients with atopic dermatitis. Clin Ther. 1997; 19 (4): 710–719.
Игнатьев Д.В., Кочергин Н.Г
.
Местные кортикостероиды в практике врача- дерматолога. Особенности гидрокортизона бутирата (локоида). Дерматология. Приложение к журналу ConsiliumMedicum. 2007; 1: 50–54.
Udompataikul M., Limpa-o-Vart D. Comparative trial of 5% dexpanthenol in water-in-oil formulation with 1% hydrocortisone ointment in the treatment of childhood atopic dermatitis: a pilot study. J Drugs Dermatol. 2012; 11 (3): 366–374.
Udompataikul M., Srisatwaja W. Comparative trial of moisturizer containing licochalcone A vs. hydrocortisone lotion in the treatment of childhood atopic dermatitis: a pilot study. J Eur Acad Dermatol Venereol. 2011; 25 (6): 660–665.
Сергеев Ю.В., Иванов О.Л., Новиков Д.К. и др. Атопический дерматит: современная диагностика и лечение. Иммунопатология, аллергология, инфектология. 2001; 4: 39– 63.
Ashcroft D.M., Dimmock P., Garside R. et al. Efficacy and tolerability of topical pimecrolimus and tacrolimus in the treatment of atopic dermatitis: meta-analysis of randomised controlled trials. BMJ. 2005; 330 (7490): 516.
Ruzicka T., Bieber T., Schöpf E. et al. A short-term trial of tacrolimus ointment for atopic dermatitis. N Engl J Med. 1997; 337 (12): 816–821.
Reitamo S., Wollenberg A., Schöpf E. et al. Safety and efficacy of 1 year of tacrolimus ointment monotherapy in adults with atopic dermatitis. Arch Dermatol. 2000; 136 (8): 999– 1006.
Chen S.L., Yan J., Wang F.S. Two topical calcineurin inhibitors for the treatment of atopic dermatitis in pediatric patients: a meta-analysis of randomized clinical trials. J DermatologTreat. 2010; 21 (3): 144–156.
Bornhövd E.C., Burgdorf W.H., Wollenberg A. Immunomodulatory macrolactams for topical treatment of inflammatory skin diseases. CurrOpinInvestig Drugs. 2002; 3 (5): 708– 712.
Lubbe J. Klinische Erfahrungen mit topischen Calcineurininhibitoren in der Praxis. Hautarzt. 2003; 54 (5): 432–439.
Reitamo S., Ortonne J.P., Sand C. et al. A multicentre, randomized, double-blind, controlled study of long-term treatment with 0.1% tacrolimus ointment in adults with moderate to severe atopic dermatitis. Br J Dermatol. 2005; 152 (6): 1282–1289.
Patel R.R., Vander Straten M.R., Korman N.J. The safety and efficacy of tacrolimus therapy in patients younger than 2 years with atopic dermatitis. Arch Dermatol. 2003; 139 (9): 1184– 1186.
Wollenberg A., Sidhu M.K., Odeyemi I. et al. Economic evaluation of maintenance treatment with tacrolimus 0.1% ointment in adults with moderate to severe atopic dermatitis. Br J Dermatol. 2008; 159 (6): 1322–1330.
Healy E., Bentley A., Fidler C., Chambers C. Cost-effectiveness of tacrolimus ointment in adults and children with moderate and severe atopic dermatitis: twice-weekly maintenance treatment vs. standard twicedaily reactive treatment of exacerbations from a third party payer (U.K. National Health Service) perspective. Br J Dermatol 2011; 164 (2): 387–395.
Reitamo S., Mandelin J., Rubins A. et al. The pharmacokinetics of tacrolimus after first and repeated dosing with 0.03% ointment in infants with atopic dermatitis. Int J Dermatol. 2009; 48 (4): 348–355.
Reitamo S., Rustin M., Harper J. et al. A 4-year follow-up study of atopic dermatitis therapy with 0.1% tacrolimus ointment in children and adult patients. Br J Dermatol. 2008; 159 (4): 942–951.
Mandelin J.M., Remitz A., Virtanen H.M. et al. A 10-year open follow-up of eczema and respiratory symptoms in patients with atopic dermatitis treated with topical tacrolimus for the first 4 years. J Dermatolog Treat. 2010; 21 (3): 167–170.
Mandelin J., Remitz A., Virtanen H.M. et al. One-year treatment with 0.1% tacrolimus ointment versus a corticosteroid regimen in adults with moderate to severe atopic dermatitis: a randomized, double-blind, comparative trial. Acta Derm Venereol. 2010; 90 (2): 170–174.
Boguniewicz M., Fiedler V.C., Raimer S. et al. A randomized, vehicle-controlled trial of tacrolimus ointment for treatment of atopic dermatitis in children. PediatricTacrolimus Study Group. J AllergyClinImmunol 1998; 102: 637–644.
Елисютина О.Г., Феденко Е.С., Штырбул О.В., Ниязов Д.Д. Применение такролимуса у больных атопическим дерматитом среднетяжелого и тяжелого течения. Первый клинический опыт в России. Российский аллергологический журнал 2011; 6: 68–76.
Прошутинская Д.В., Бутарева М.М., Иноятова Л.А. Новые возможности терапии атопического дерматита у детей и взрослых. Вестник дерматологии и венерологии 2013; 3: 78–82.
Самцов А.В., Сухарев А.В., Патрушев А.В., Бондарь О.И. Клиническая эффективность, безопасность и переносимость 0,1% мази такролимус при лечении атопического дерматита средней и тяжелой степени тяжести. Вестник дерматологии и венерологии 2012; 2: 71–77.
Самцов А.В., Сухарев А.В., Патрушев А.В. Лечение атопического дерматита: преимущества такролимуса перед топическими кортикостероидами. Эффективная фармакотерапия 2014; 19: 4–10.
Van Leent E.J., Graber M., Thurston M. et al. Effectiveness of the ascomycin macrolactam SDZ ASM 981 in the topical treatment of atopic dermatitis. Arch Dermatol 1998; 134 (7): 805–809.
Meurer M., Fölster-Holst R., Wozel G. et al. Pimecrolimus cream in the long-term management of atopic dermatitis in adults: a six-month study. Dermatology 2002; 205 (3): 271–277.
Wahn U., Bos J., Goodfield M. et al. Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children. Pediatrics. 2002; 110 (1 Pt 1): 1–8.
Ho V.C., Gupta A., Kaufmann R. et al. Safety and efficacy of nonsteroid pimecrolimus cream 1% in the treatment of atopic dermatitis in infants. J Pediatr 2003; 142 (2): 155–162.
Eichenfield L.F., Lucky A.W., Boguniewicz M. et al. Safety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of mild and moderate atopic dermatitis in children and adolescents. J Am Acad Dermatol. 2002; 46 (4): 495–504.
Langley R.G., Eichenfield L.F., Lucky A.W. et al. Sustained efficacy and safety of pimecrolimus cream 1% when used long-term (up to 26 weeks) to treat children withatopic dermatitis. Pediatr Dermatol. 2008; 25 (3): 301–307.
Luger T., van Leent E.J., Graeber M. et al. SDZ ASM 981: an emerging safe and effective treatment for atopic dermatitis. Br J Dermatol. 2001; 144 (4): 788–794.
Eichenfield L.F., Thaci D., de Prost Y. et al. Clinical management of atopic eczema with pimecrolimus cream 1% (Elidel) in paediatric patients. Dermatology 2007; 11: 3–17.
Reda A.M., Elgendi A., Ebraheem A.I, et al. A practical algorithm for topical treatment of atopic dermatitis in the Middle East emphasizing the importance of sensitive skin areas. J Dermatolog Treat. 2019; 30 (4): 366–373.
Кубанов А.А., Петровский Ф.И. Активированный пиритион цинка (Скин-кап). Механизмы действия. Клиническое применение. Вестник дерматологии и венерологии, 2009; 5: 35–42.
Фассахов Р.С., Пампура А.Н., Коростовцев Д.С. и др. Скин-Кап в терапии атопического дерматита у детей (по результатам Российского многоцентрового исследования КАДЕТ). Российский Аллергологический Журнал 2007; 2: 75–81.
Фассахов Р.С., Пампура А.Н., Коростовцев Д.С. и др. Эффективность и безопасность активированного цинк пиритиона (скин-кап) в лечении атопического дерматита у детей (результаты Российского многоцентрового исследования). Вестник педиатрической фармакологии и нутрициологии 2006; 3 (6): 28–31.
Нейродерматозы. В кн.: Кожные и венерические болезни: Руководство для врачей. В двух томах. – 2-е изд., перераб. и доп. – Т.2/ Под ред. Ю.К. Скрипкина и В.Н. Мордовцева, - М.: Медицина, 1999. – С.9–49.
Yoshida H., Niimura M., Ueda H. et al. Clinical evaluation of ketotifen syrup on atopic dermatitis: a comparative multicenter double-blind study of ketotifen and clemastine. Ann Allergy. 1989; 62 (6): 507–512.
Григорьева И., Сергеев А., Манина И., Кудрявцева Е. Иммунопатология и биохимические основы атопических состояний. Врач. 2012; 4: 86–91.
Морозова С.В., Лусс Л.В. Хлоропирамин: современные аспекты применения. Вопросы современной педиатрии. 2007; 6 (1): 137–140.
Горячкина М.В., Белоусова Т.А. Хлоропирамин: клинические аспекты применения. Русский медицинский журнал. Аллергология. 2014; 24: 1785–1789.
Петрова К.С., Петрова Г.А. Хлоропирамин (Супрастин) – современные аспекты применения в терапии аллергодерматозов. Русский медицинский журнал. Фармакотерапия. 2014; 8: 617–620.
Ревякина В.А. Антигистаминные препараты в клинической практике. Русский медицинский журнал. Аллергология. 2014; 11: 854–856.
Behrendt H., Ring J. Histamine, antihistamines and atopic eczema. Clin Exp Allergy. 1990;20 (Suppl 4): 25–30.
Langeland T., Fagertun H.E., Larsen S. Therapeutic effect of loratadine on pruritus in patients with atopic dermatitis. A multi-crossover-designed study. Allergy. 1994; 49 (1): 22– 26.
Monroe E.W. Relative efficacy and safety of loratadine, hydroxyzine, and placebo in chronic idiopathic urticaria and atopic dermatitis. Clin Ther. 1992; 14 (1): 17–21.
Попова И.С., Матушевская Е.В., Свирщевская Е.В. Двойное слепое плацебо– контролируемое исследование эффективности и переносимости кларотадина при атопическом дерматите. Русс. Мед. Журн. Дерматология, Венерология. 2001; 9 (4): 477–483.
Hannuksela M., Kalimo K., Lammintausta K. et al. Dose ranging study: cetirizine in the treatment of atopic dermatitis in adults. Ann Allergy. 1993; 70 (2): 127–133.
La Rosa M., Ranno C., Musarra I. et al. Double-blind study of cetirizine in atopic eczema in children. Ann Allergy 1994; 73 (2): 117–122.
Павлова О.В. Опыт применения цетиризина (аллертека) в терапии больных атопическим дерматитом и экземой. Вестник дерматологии и венерологии 2005; (4): 41–43.
Макарова И.В., Жиглинская О.В., Михайлова Е.А., Сухорукова В.Г. Сравнительная эффективность препаратов цетиризина дженерика (производство Эгис, Венгрия) и оригинального в форме капель в комплексной терапии атопического дерматита у детей раннего возраста. Вопросы современной педиатрии. 2007; 6 (3): 85–88.
Самсыгина Г.А. Аллергические болезни у детей. – М.: ГЭОТАР-Медиа, 2019. – 272 с.
Делягин В.М., Уразбагамбетов А. Применение Cупрастинекса (левоцетиризина) при атопии у детей и подростков. Русский медицинский журнал. Педиатрия 2012; (16): 828–830.
Елисютина О.Г., Феденко Е.С., Федоскова Т.Г., Лусс Л.В. Эффективность терапии левоцетиризином больных с аллергодерматозами. Росс. Аллергол. Журнал, 2012,5: 69- 75
Тамразова О.Б. Патогенетическая терапия детей, страдающих тяжелыми формами атопического дерматита. Русский медицинский журнал. Педиатрия. 2013; (2): 108–114.
Нажмутдинова Д.К., Швец О.И. Левоцетиризин: перезагрузка. Русский медицинский журнал. Дерматология. 2011; 21: 1324–1326.
Камаев А.В., Трусова О.В., Камаева И.А. Зуд при атопическом дерматите у детей: известные механизмы и возможности его долгосрочного контроля. Русский медицинский журнал. 2015; 3: 142–146.
Монахов С. А., Коржачкина Н. Б., Олисова О. Ю. Узковолновая фототерапия 311 нм в лечении больных атопическим дерматитом. Российский журнал кожных и венерических болезней. 2012; 3: 25–27.
Majoie I.M., Oldhoff J.M., van Weelden H. et al. Narrowband ultraviolet B and medium- dose ultraviolet A1 are equally effective in the treatment of moderate to severe atopic dermatitis. J Am Acad Dermatol 2009; 60: 77–84.
Reynolds N.J., Franklin V., Gray J.C. et al. Narrow-band ultraviolet B and broad-band ultraviolet A phototherapy in adult atopic eczema: a randomised controlled trial. Lancet. 2001; 357 (9273): 2012–2016.
Clayton T.H., Clark S.M., Turner D., Goulden V. The treatment of severe atopic dermatitis in childhood with narrowband ultraviolet B phototherapy. Clin Exp Dermatol. 2007; 32 (1): 28–33.
Seccombe L., Wynne M.D., Clancy C. et al. A retrospective review of phototherapy in children, at a tertiary paediatric dermatology unit. Photodermatol Photoimmunol Photomed. 2021; 37 (1): 34–38.
Gambichler T., Othlinghaus N., Tomi N.S. et al. Medium-dose ultraviolet (UV) A1 vs. narrowband UVB phototherapy in atopic eczema: a randomized crossover study. Br J Dermatol 2009; 160 (3): 652–658.
Bogaczewicz J., Malinowska K., Sysa-Jedrzejowska A., Wozniacka A. Medium-dose ultraviolet A1 phototherapy improves SCORAD index and increases mRNA expression of interleukin-4 without direct effect on human β defensin-1, interleukin-10, and interleukin-31. Int J Dermatol. 2016; 55 (7): e380–e385.
TzanevaS.,Seeber A., Schwaiger M. et al. High-dose versus medium-dose UVA1 phototherapy for patients with severe generalized atopic dermatitis. J Am Acad Dermatol. 2001; 45: 503–507.
Malinowska K., Wozniacka A., Bogaczewicz J. The impact of medium dose UVA1 phototherapy on pruritus, DLQI and SCORAD index in patients with atopic dermatitis. Postepy Dermatol Alergol. 2020; 37 (6): 962–967.
Abeck D., Schmidt T., Fesq H. et al. Long-term efficacy of medium-dose UVA1 phototherapy in atopic dermatitis. J Am Acad Dermatol. 2000; 42 (2 Pt 1): 254–257.
Pugashetti R., Lim H.W., Koo J. Broadband UVB revisited: is the narrowband UVB fad limiting our therapeutic options? J DermatologTreat. 2010; 21 (6): 326–330.
Tzaneva S., Kittler H., Holzer G. et al. 5-Methoxypsoralen plus ultraviolet (UV) A is superior to medium-dose UVA1 in the treatment of severe atopic dermatitis: a randomized crossover trial. Br J Dermatol. 2010; 162 (3): 655–660.
Garritsen F.M., Brouwer M.W., Limpens J., Spuls P.I. Photo(chemo)therapy in the management of atopic dermatitis: an updated systematic review with implications for practice and research. Br J Dermatol. 2014; 170 (3): 501–513.
Pérez-Ferriols A., Aranegui B., Pujol-Montcusí J.A. et al. Phototherapy in atopic dermatitis: a systematic review of the literature. Actas Dermosifiliogr. 2015; 106 (5): 387– 401.
Uetsu N., Horio T. Treatment of persistent severe atopic dermatitis in 113 Japanese patients with oral psoralen photo-chemotherapy. J Dermatol. 2003; 30 (6): 450–457.
Физическая и реабилитационная медицина. Национальное руководство. / Под ред. Г.Н. Пономаренко., М.: ГЭОТАР-Медиа, 2016 г. 688 с.
Частная физиотерапия:Учебное пособие / Под ред.Г.Н. Пономаренко. — М.: ОАО «Издательство «Медицина», 2005, 744 с.
Patrizi A., Raone B., Ravaioli G.M. Management of atopic dermatitis: safety and efficacy of phototherapy. ClinCosmetInvestig Dermatol. 2015; 8: 511–520.
Dogra S., Mahajan R.; Indian Association of Dermatologists, Venereologists and Leprologists. Phototherapy for atopic dermatitis. Indian J Dermatol VenereolLeprol. 2015; 81 (1): 10–15.
Кубанова А.А., Самсонов В.А., Волнухин В.А. и др. Терапия больных псориазом, атопическим дерматитом и витилиго узкополосным средневолновым ультрафиолетовым излучением с длиной волны 311 нм. Медицинская технология № ФС-2006/250 от 15 августа 2006 года. Вестник дерматологии и венерологии 2008; 3: 17–20.
Thompson K.G., Kim N. Distinguishing myth from fact: photocarcinogenesis and phototherapy.DermatolClin. 2020; 38 (1): 25–35.
Paller A.S., Siegfried E.C., Thaçi D. et al. Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: A randomized, double-blinded, placebo-controlled phase 3 trial. J Am Acad Dermatol. 2020; 83 (5): 1282–1293.
Paller A.S., Bansal A., Simpson E.L. et al. Clinically meaningful responses to dupilumab in adolescents with uncontrolled moderate-to-severe atopic dermatitis: Post-hoc analyses from a randomized clinical trial. Am J Clin Dermatol. 2020; 21 (1): 119–131.
Simpson E.L., Paller A.S., Siegfried E.C. et al. Efficacy and safety of dupilumab in adolescents with uncontrolled moderate to severe atopic dermatitis: A phase 3 randomized clinical trial. JAMA Dermatol. 2020; 156 (1): 44–56.
Cork M.J., Thaçi D., Eichenfield L.F. et al. Dupilumab in adolescents with uncontrolled moderate-to-severe atopic dermatitis: results from a phase IIa open-label trial and subsequent phase III open-label extension. Br J Dermatol. 2020; 182 (1): 85–96.
Simpson E.L., Bieber T., Guttman-Yassky E. et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016; 375 (24): 2335–2348.
Blauvelt A., de Bruin-Weller M., Gooderham M. et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet 2017; 389 (10086): 2287–2303.
de Bruin-Weller M., Thaçi D., Smith C.H. et al. Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo- controlled, randomized phase III clinical trial (LIBERTY AD CAFÉ). Br J Dermatol. 2018;178(5):1083–1101.
Thaçi D., L Simpson E., Deleuran M. et al. Efficacy and safety of dupilumab monotherapy in adults with moderate-to-severe atopic dermatitis: a pooled analysis of two phase 3 randomized trials (LIBERTY AD SOLO 1 and LIBERTY AD SOLO 2). J Dermatol Sci. 2019; 94 (2): 266–275.
Cork M.J., Eckert L., Simpson E.L. et al. Dupilumab improves patient-reported symptoms of atopic dermatitis, symptoms of anxiety and depression, and health-related quality of life in moderate-to-severe atopic dermatitis: analysis of pooled data from the randomized trials SOLO 1 and SOLO 2. J Dermatolog Treat. 2019 Jun 9:1–9.
Snast I., Reiter O., Hodak E. et al. Are biologics efficacious in atopic dermatitis? asystematic review and meta-analysis. Am J Clin Dermatol. 2018; 19 (2):145–165.
Wang F.P., Tang X.J., Wei C.Q. et al. Dupilumab treatment in moderate-to-severe atopic dermatitis: A systematic review and meta-analysis. J Dermatol Sci. 2018; 90 (2):190–198.
Czech W., Brautigam M., Weidinger G., Schöpf E. Body weight independent dosing regimen of cyclosporine microemulsion is effective in severe atopic dermatitis and improves the quality of life. J Am Acad Dermatol 2000; 42: 653–659.
Harper J.I., Ahmed I., Barclay G. et al. Cyclosporin for severe childhood atopic dermatitis: short course versus continuous therapy. Br J Dermatol 2000; 142: 52–58.
Granlund H., Erkko P., Remitz A. et al. Comparison of cyclosporin and UVAB phototherapy for intermittent one-year treatment of atopic dermatitis. Acta DermVenereol 2001; 81: 22–27.
Zurbriggen B., Wuthrich B., Cachelin A.B. et al. Comparison of two formulations of cyclosporin A in the treatment of severe atopic dermatitis. A double-blind, single-centre, cross-over pilot study. Dermatology 1999; 198: 56–60.
Hijnen D.J., ten Berge O., Timmer-de Mik L.et al. Efficacy and safety of long-term treatment with cyclosporin A for atopic dermatitis. J Eur Acad Dermatol Venereol 2007; 21: 85–89.
Schmitt J., Schmitt N., Meurer M. Cyclosporin in the treatment of patients with atopic eczema a systematic review and meta-analysis. J Eur Acad Dermatol Venereol 2007; 21 (5): 606–619.
Amor K.T., Ryan K., Menter A. The use of cyclosporine in dermatology: Part I. J Am Acad Dermatol 2010; 63 (6): 925–946.
WollenbergA., BarbarotS., Bieber T. et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part II. JEur AcadDermatol Venereol 2018; 32 (6): 850–878.
Шамов Б.А. Атопический дерматит: клинические проявления и лечение. Дневник Казанской медицинской школы. 2014; 1 (4): 63–65.
Jung M.Y., Chung J.Y., Lee H.Y. et al. Antibiotic susceptibility of Staphylococcus aureus in atopic dermatitis: current prevalence of methicillin-resistant Staphylococcus aureus in Korea and treatment strategies. Ann Dermatol. 2015; 27 (4): 398–403.
Lübbe J. Secondary infections in patients with atopic dermatitis. Am J ClinDermatol 2003; 4 (9): 641–654.
Масюкова С.А., Гладько Е.В., Тарасенко Г.Н. и др. Фузидиевая кислота в лечении пиодермитов и аллергодерматозов, осложненных бактериальной инфекцией. Вестник дерматологии и венерологии. 2007; 6: 54–57.
Дворянкова Е.В., Корсунская И.М., Захарова А.Б., Жуковский Р.О. Атопический дерматит, осложненный вторичной инфекцией: подходы к терапии. Эффективная фармакотерапия. 2011; 26: 74–76.
Ларькова И.А. Эффективная терапия атопического дерматита у детей, осложненного вторичной инфекцией. Медицинский совет. 2016; 1: 162–167.
Матушевская Е.В., Свирщевская Е.В. Атопический дерматит в практике врача- дерматовенеролога: рациональный выбор терапии. Русский медицинский журнал. 2013; 21 (8): 410–412.
Gong J.Q., Lin L., Lin T. et al. Skin colonization by Staphylococcus aureus in patients with eczema and atopic dermatitis and relevant combined topical therapy: a double-blind multicentre randomized controlled trial. Br J Dermatol 2006; 155: 680–687.
Lever R, Hadley K, Downey D, Mackie R. Staphylococcal colonization in atopic dermatitis and the effect of topical mupirocin therapy. Br J Dermatol 1988; 119:189–198.
Альбанова В. Наружное лечение атопического дерматита. Врач. 2006; 2: 76–78.
Батыршина С.В., Хаертдинова Л.А. Концепция местной терапии больных атопическим дерматитом. Практическая медицина. 2009; 35 (3): 41–45.
Wachs G.N., Maibach H.I. Co-operative double-blind trial of an antibiotic ⁄ corticoid combination in impetiginized atopic dermatitis. Br J Dermatol 1976; 95: 323–328.
Schuttelaar M.L., Coenraads P.J. A randomized, double-blind study to assess the efficacy of addition of tetracycline to triamcinolone acetonide in the treatment of moderate to severe atopic dermatitis. J EurAcadDermatolVenereol 2008; 22: 1076–1082.
Васенова В.Ю., Бутов Ю.С. Применение Полькортолона ТС для лечения зудящих дерматозов, осложненных вторичной инфекцией. Русский медицинский журнал 2013; 21 (22): 1096–1098.
Скрипкин Ю.К., Хамаганова И.В. Опыт применения аэрозолей оксикорт и полькортолон ТС в лечении аллергических дерматозов, осложненных пиодермией. Вестник дерматологии и венерологии. 2004; 1: 42–43.
Ramsay C., Savoie J., Gilbert M. et al. The treatment of atopic dermatitis with topical fusidic acid and hydrocortisone acetate. J Eur Acad Dermatol Venereol 1996; 7 (Suppl. 1):S15–22.
Hjorth N., Schmidt H., Thomsen K. Fusidic acid plus betamethasone in infected or potentially infected eczema. Pharmatherapeutica 1985; 4: 126–131.
Тарасова М.В., Марина Т.В., Сорокина Е.А. и др. Целесообразность применения комбинированных топических глюкокортикостероидов в комплексной терапии атопического дерматита. Журнал научных статей Здоровье и образование в XXI веке. 2008; 10 (3): 383.
Кубанова А.А. Прошутинская Д.В., Текучева Л.В., Авдиенко И.Н. Интегральный подход к наружной терапии больных атопическим дерматитом. Вестник дерматологии и венерологии. 2010; 1: 20–26.
Ненашева Н.М. Особенности местной (наружной) терапии осложненного инфекцией атопического дерматита. РМЖ. 2015; 23 (19): 1159–1165.
Кунгуров Н.В., Кениксфест Ю.В., Кохан М.М. и др. Комбинированная наружная терапия осложненных дерматозов. Клиническая дерматология и венерология. 2005; 2: 33–37.
Niebuhr M., Mai U., Kapp A., Werfel T. Antibiotic treatment of cutaneous infections with Staphylococcus aureus in patients with atopic dermatitis: current antimicrobial resistances and susceptibilities. ExpDermatol. 2008; 17 (11): 953–957.
Boguniewicz M., Sampson H., Leung S. et al. Effects of cefuroxime axetil on Staphylococcus aureus colonizing and superantigen production in atopic dermatitis. J Allergy Clin Immunol 2001; 108: 651–652.
Тренева М.С., Пампура А.Н. Стратегия выбора антибактериальных препаратов у детей с микробным инфицированием атопического дерматита. Практическая медицина. 2011; 3 (51): 136–139.
Boguniewicz M., Leung D.Y. Recent insights into atopic dermatitis and implications for management of infectious complications. J AllergyClinImmunol. 2010; 125 (1): 4–13.
Tognetti L., Martinelli C., Berti S. et al. Bacterial skin and soft tissue infections: review of the epidemiology, microbiology, aetiopathogenesis and treatment: a collaboration between dermatologists and infectivologists. J Eur Acad Dermatol Venereol. 2012; 26 (8): 931–941.
Petry V., Bessa G.R., Poziomczyck C.S. et al. Bacterial skin colonization and infections in patients with atopic dermatitis. An Bras Dermatol. 2012; 87 (5): 729–734.
Wollenberg A. Eczema herpeticum. Chem Immunol Allergy. 2012; 96: 89–95.
Niimura M., Nishikawa T. Treatment of eczema herpeticum with oral acyclovir. Am J Med.1988; 85 (2A): 49–52.
Bussmann C., Bockenhoff A., Henke H. et al. Does allergen-specific immunotherapy represent a therapeutic option for patients with atopic dermatitis? J Allergy Clin Immunol 2006; 118: 1292–1298.
Darsow U., Forer I., Ring J. Allergen-specific immunotherapy in atopic eczema. Curr Allergy Asthma Rep 2011; 11: 277–283.
Bae J.M., Choi Y.Y., Park C.O. et al. Efficacy of allergen-specific immunotherapy for atopic dermatitis: a systematic review and meta-analysis of randomized controlled trials. J Allergy Clin Immunol 2013; 132: 110–117.
Ring J. Successful hyposensitization treatment in atopic eczema: results of a trial in monozygotic twins. Br J Dermatol 1982; 107: 597–602.
Glover M.T., Atherton D.J. A double-blind controlled trial of hyposensitization to Dermatophagoidespteronyssinus in children with atopic eczema. Clin Exp Allergy 1992; 22: 440–446.
Zachariae H., Cramers M., Herlin T.etal. Non-specific immunotherapy and specific hyposensitization in severe atopic dermatitis. Acta Derm Venereol Suppl (Stockh) 1985; 114: 48–54.
Елисютина О.Г., Феденко Е.С. Место специфической иммунотерапии в лечении больных атопическим дерматитом, осложненным рецидивирующей пиодермией. Физиология и патология иммунной системы. Физиология и патология иммунной системы. 2006;(8): С.15.
Novak N., BieberT., Hoffmann M. et al. Efficacy and safety of subcutaneous allergen- specific immunotherapy with depigmented polymerized mite extract in atopic dermatitis. J Allergy Clin Immunol 2012; 130: 925– 931 e4.
Pajno G.B., Caminiti L., Vita D. et al. Sublingual immunotherapy in mite-sensitized children with atopic dermatitis: a randomized, double-blind, placebo-controlled study. J Allergy Clin Immunol 2007; 120: 164–170.
Qin Y.E., Mao J.R., Sang Y.C., Li W.X. Clinical efficacy and compliance of sublingual immunotherapy with Dermatophagoidesfarinae drops in patients with atopic dermatitis. Int J Dermatol 2014; 53: 650–655.
Liu L., Guo D., Liang Q. et al. The efficacy of sublingual immunotherapy with Dermatophagoidesfarinae vaccine in a murine atopic dermatitis model. Clin Exp Allergy 2015; 45: 815–822.
Roduit C., Frei R., Loss G. et al. Development of atopic dermatitis according to age of onset and association with early-life exposures. J Allergy Clin Immunol 2012; 130: 130–136 e5.
Perkin M.R., Logan K., Tseng A. et al. Randomized trial of introduction of allergenic foods in breast-fed infants. N Engl J Med 2016; 374: 1733–1743.
Prell C., Koletzko B. Breastfeeding and Complementary Feeding. DtschArztebl Int. 2016;113(25):435–444.
Vandenplas Y., Al-Hussaini B., Al-Mannaei K. et al. Prevention of Allergic Sensitization and Treatment of Cow's Milk Protein Allergy in Early Life: The Middle-East Step-Down Consensus. Nutrients. 2019 Jun 26;11(7).
Gruber C. Probiotics and prebiotics in allergy prevention and treatment: future prospects. Exp Rev Clin Immunol 2012; 8: 17 –19.
Cuello-Garcia C.A., Brozek J.L., Fiocchi A. et al. Probiotics for the prevention of allergy: a systematic review and meta-analysis of randomized controlled trials. J Allergy Clin Immunol 2015; 136: 952–961.
PanduruМ., Panduru N.M., Sălăvăstru C.M., Tiplica G.S. Probiotics and primary prevention of atopic dermatitis: a meta-analysis of randomized controlled studies. J Eur Acad Dermatol Venereol 2015; 29 (2): 232–242.
Muraro A., Halken S., Arshad S.H. et al. EAACI food allergy and anaphylaxis guidelines. Primary prevention of food allergy. Allergy 2014; 69: 590–601.
Kantor R., Kim A., Thyssen J.P., Silverberg J.I. Association of atopic dermatitis with smoking: a systematic review and meta-analysis. J Am Acad Dermatol 2016; 75: 1119–1125 e1.
Kathuria P., Silverberg J.I. Association of pollution and climate with atopic eczema in US children. Pediatr Allergy Immunol 2016; 27: 478–485.
Morgenstern V., Zutavern A., Cyrys J. et al. Atopic diseases, allergic sensitization, and exposure to traffic-related air pollution in children. Am J Respir Crit Care Med 2008; 177: 1331–1337.
Hidaka T., Ogawa E., Kobayashi E.H. et al. The aryl hydrocarbon receptor AhR links atopic dermatitis and air pollution via induction of the neurotrophic factor artemin. Nat Immunol 2017; 18: 64–73.
Ricci G., Bendandi B., Aiazzi R.et al. Three years of Italian experience of an educational program for parents of young children affected by atopic dermatitis: improving knowledge produces lower anxiety levels in parents of children with atopic dermatitis. Pediatr Dermatol. 2009; 26:1–5.
Staab D., Diepgen T.L., Fartasch M. et al. Age related, structured educational programmes for the management of atopic dermatitis in children and adolescents: multicentre, randomised controlled trial. BMJ. 2006; 332:933–938.
Lambert J., Bostoen J., Geusens B. et al. A novel multidisciplinary educational programme for patients with chronic skin diseases: Ghent pilot project and first results. Arch Dermatol Res. 2011; 303:57–63.
Kupfer J., Gieler U., Diepgen T.L. et al. Structured education program improves the coping with atopic dermatitis in children and their parents-a multicenter, randomized controlled trial. J PsychosomRes. 2010; 68 (4):353–358.
Staab D., von Rueden U., Kehrt R. et al. Evaluation of a parental training program for the management of childhood atopic dermatitis. Pediatr Allergy Immunol. 2002; 13:84–90.
Kiriyama T., Sugiura H., Uehara M. Residual washing detergent in cotton clothes: a factor of winter deterioration of dry skin in atopic dermatitis. J Dermatol. 2003; 30:708–712.
Schmid-Wendtner M.H., Korting H.C. The pH of the skin surface and its impact on the barrier function. Skin Pharmacol Physiol. 2006; 19: 296–302.
Simpson E., Trookman N.S., Rizer R.L. et al. Safety and tolerability of a body wash and moisturizer when applied to infants and toddlers with a history of atopic dermatitis: results from an open-label study. Pediatr Dermatol. 2012; 29:590–597.
Hon K.L., Leung T.F., Wong Y. et al. A survey of bathing and showering practices in children with atopic eczema. Clin Exp Dermatol. 2005; 30:351–354.
Wollenberg A., Vogel S., Renner E.D. [Vaccinations with atopic dermatitis and other chronic inflammatory skin diseases]. Hautarzt 2010; 61: 985–993.
Bath-Hextall F., Delamere F., Williams H. Dietary exclusions for improving established atopic eczema in adults and children systematic review. Allergy 2009; 64: 258–264.
Электронный ресурс https://base.garant
.
ru/70647158/53f89421bbdaf741eb2d1ecc4ddb4c33/
[Аллергология и иммунология: национальное руководство / Под ред. ХаитоваР.М., Ильиной Н.И. – М.: ГЭОТАР-Медиа, 2009.
Campana R., Dzoro S., Mittermann I. et al. Molecular aspects of allergens in atopic dermatitis. CurrOpin Allergy Clin Immunol. 2017;17(4):269–277.
Cartledge N, Chan S. Atopic Dermatitis and Food Allergy: A Paediatric Approach. CurrPediatr Rev. 2018;14(3):171-179. doi: 10.2174/1573396314666180613083616. PMID: 29895253.
Darsow U., Laifaoui J., Kerschenlohr K. et al. The prevalence of positive reactions in the atopy patch test with aeroallergens and food allergens in subjects with atopic eczema: A European multicenter study. Allergy. 2004;59:1318–1325.
Tamagawa-Mineoka R., Katoh N. Atopic Dermatitis: Identification and Management of Complicating Factors. Int J Mol Sci. 2020; 21 (8): 2671.
Werfel T., Heratizadeh A., Niebuhr M.et al. Exacerbation of atopic dermatitis on grass pollen exposure in an environmental challenge chamber. J Allergy Clin Immunol. 2015;136(1):96–103.e9.
Caut C., Leach M., Steel A. Dietary guideline adherence during preconception and pregnancy: A systematic review. Matern Child Nutr. 2020;16(2):e12916.
Sugita K., Akdis C.A. Recent developments and advances in atopic dermatitis and food allergy. Allergol Int. 2020; 69 (2): 204–214.
Fedenko E., Elisyutina O., Shtyrbul O.et al. Microarray-based IgE serology improves management of severe atopic dermatitis in two children. Pediatr Allergy Immunol. 2016;27(6):645–649.
Alexander D.D., Cabana M.D. Partially hydrolyzed 100% whey protein infant formula and reduced risk of atopic dermatitis: a meta-analysis. J Pediatr Gastroenterol Nutr. 2010; 50 (4): 422–430.
Niggemann B., Reibel S., Wahn U. The atopy patch test (APT)–a useful tool for the diagnosis of food allergy in children with atopic dermatitis //Allergy. – 2000. – Т. 55. – №. 3. – С. 281-285.
Sampson H. A., Albergo R. Comparison of results of skin tests, RAST, and double-blind, placebo-controlled food challenges in children with atopic dermatitis //Journal of Allergy and Clinical Immunology. – 1984. – Т. 74. – №. 1. – С. 26-33.
Roehr C. C. et al. Atopy patch tests, together with determination of specific IgE levels, reduce the need for oral food challenges in children with atopic dermatitis //Journal of allergy and clinical immunology. – 2001. – Т. 107. – №. 3. – С. 548-553.
Для продолжения работы требуется
Регистрация
Предыдущая страница
Следующая страница
Оглавление
Список сокращений
Термины и определения
Атопический дерматит
+
7. Дополнительная информация (в том числе факторы, влияющие на исход заболевания или состояния)
+
Список литературы
Приложение А1. Состав рабочей группы по разработке и пересмотру клинических рекомендаций
Приложение А2. Методология разработки клинических рекомендаций
Приложение А3. Справочные материалы, включая соответствие показаний к применению и противопоказаний, способов применения и доз лекарственных препаратов инструкции по применению лекарственного препарата
Приложение Б. Алгоритмы действий врача
Приложение В. Информация для пациента
Приложение Г. Шкалы оценки, вопросники и другие оценочные инструменты состояния пациента, приведенные в клинических рекомендациях
+
Данный блок поддерживает скрол*